Income Statement

v3.22.4

Consolidated Statements of Operations and Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Revenues
Royalty	$ 2,911	$ 0
Service	92,488	0
Product	210,993	90,035
Total Revenues	306,392	90,035
Operating Expenses
Research and development	14,572,532	13,022,411
General and administrative	10,937,686	11,676,446
Sales and marketing	6,576,246	3,724,257
Total Operating Expenses	32,086,464	28,423,114
Operating Loss	(31,780,072)	(28,333,079)
Other Income (Expenses)
Grant income	1,229,425	1,522,533
Loss on disposal of fixed assets	0	(26,166)
Interest income	125,265	2,734
Interest expense	(173,087)	(155,803)
Total Other Income	1,181,603	1,343,298
Net Loss	(30,598,469)	(26,989,781)
Net Loss attributable to Non-Controlling Interest	329,676	175,116
Net Loss attributable to VolitionRx Limited Stockholders	(30,268,793)	(26,814,665)
Other Comprehensive Income (Loss)
Foreign currency translation adjustments	78,771	208,304
Net Comprehensive Loss	$ (30,519,698)	$ (26,781,477)
Net Loss Per Share - Basic and Diluted attributable to VolitionRx Limited Stockholders	$ (0.55)	$ (0.51)
Weighted Average Shares Outstanding
- Basic and Diluted	55,350,401	52,655,885

- Definition

The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.4)
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

Source